Pipelines and Preparation: How the US Can Prepare for More RA Biosimilars

With 1 adalimumab biosimilar and 3 infliximab biosimilars on the market, and over 10 more biosimilars for rheumatoid arthritis (RA) coming down the pipeline, rheumatologists are about to have more treatment choices for their patients than ever before. 2023 marks the US introductions of biosimilar referencing Humira (adalimumab) and Stelara (ustekinumab). With an abundance of choice, come storage, education, and payer challenges. What can practices do to prepare? How can they boost uptake of these products? And how can we ensure that the lower than anticipated uptake of infliximab biosimilars is not repeated?

Today, I’m speaking with Robert Zutaut, RPh, clinical specialist with McKesson Provider Solutions about the influx of these RA biosimilars and actions that clinicians can take to prepare for the large number of products expected to hit the market in the next couple years. Prior to his work with McKesson, he served as the director of pharmaceutical services at Raleigh Regional Cancer Center in Beckley, West Virginia. He obtained a bachelor of pharmacy from West Virginia University and has been analyzing RA biosimilar trends and the everchanging market. He’s also been keeping an eye on the development for prognostic biomarker tests in the RA space.

Show notes

To learn more about biosimilars to treat RA, click here.

To learn more about rheumatologists’ perceptions about RA biosimilars, click here.

To learn more about incentives for prescribing biosimilars, click here.

To learn more about infliximab biosimilar adoption, click here.

To learn more about the influx of adalimumab biosimilars to the US market, click here.

To learn more about ustekinumab biosimilars, click here.

Keep a lookout for Robert's upcoming contributor article on the developing RA biosimilar market.